Combined SPG7 and AFG3L2 Mutations Are Associated with Late-Onset Ataxia and Pyramidal Signs

Category	Detail
Condition	Late-onset cerebellar ataxia associated with heterozygous variants in SPG7 and AFG3L2
Key Mechanisms	SPG7 and AFG3L2 form hetero-oligomers in the mitochondrial m-AAA protease complex; variants in both genes may disrupt complex function and mitochondrial proteostasis.
Target Population	People with ataxia in whom genetic testing identifies potentially relevant variants in SPG7 and AFG3L2.
Care Setting	Specialist neurological and genetic evaluation, including ataxia assessment, variant interpretation, and follow-up.

The report describes a patient with ataxia beginning at approximately 45 years of age and heterozygous variants in both SPG7 and AFG3L2.
Clinical findings included predominantly lower-limb ataxia, broad-based gait, hyperreflexia, and later progressive oculomotor dysfunction and bilateral ptosis.
The authors consider the combined variants supportive of a digenic disease mechanism, while noting that the effect could not be established definitively in their original report.
The patient also carried two heterozygous POLG pathogenic variants in cis, which were considered unlikely to explain the phenotype.
The report highlights the need to prioritize and interpret multiple genetic findings carefully in ataxia evaluation and genetic counselling.

Assess the clinical phenotype, including cerebellar signs, pyramidal signs, gait, sensory function, vestibular findings, and oculomotor features.
Interpret SPG7 and AFG3L2 variants together in the context of phenotype, variant evidence, and their hetero-oligomeric relationship.
Consider that different nomenclatures may describe the same SPG7 deletion; the reported c.1450-1_1457delGGAGAGGCG and c.1454_1462del p.(Arg485_Glu487del) refer to the same variant.

Use careful variant prioritization when exome sequencing identifies multiple pathogenic, likely pathogenic, or uncertain variants.
Consider genetic counselling in the context of the identified variants and family history.

Follow clinical features over time; the reported patient had assessments spanning 15 years of disease.
Monitor gait and ataxia, pyramidal signs, oculomotor function, ptosis, hearing, and orthostatic symptoms as clinically relevant to the reported phenotype.

Multiple potentially relevant genetic findings can complicate attribution of the ataxia phenotype.
The proposed digenic mechanism is supported by the reported observations but was not definitively established in the authors’ original case report.
The patient’s isolated SFEMG abnormality was not attributed to myasthenia gravis; clinical assessment and negative antibody studies excluded that diagnosis.

The report concerns a patient with late-onset ataxia and heterozygous SPG7 and AFG3L2 variants; it does not provide prescribing or treatment data.

No drug treatment recommendations or prescribing outcomes are reported. Bilateral ptosis required surgical correction.

Correlate genetic findings with detailed neurological examination and longitudinal clinical data.
Review variant nomenclature and predicted splice effects when interpreting SPG7 variants.
Evaluate co-occurring variants rather than assuming that each pathogenic or likely pathogenic finding explains the phenotype.
Use family history in genetic assessment; maternal DNA was unavailable in the reported case.

Clinical Scorecard: Combined SPG7 and AFG3L2 Mutations Are Associated with Late-Onset Ataxia and Pyramidal Signs